{"company":{"slug":"r1-therapeutics","name":"R1 Therapeutics","stage":"series-a","industry":"bio-health","subcategory":null,"sector":"Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics","description":"R1 Therapeutics is a clinical-stage biopharmaceutical company that develops first-in-class treatments for kidney disease patients.","crypto":false,"first_seen_at":"2026-10-04T09:36:37.197Z","hq_city":"London","hq_country":"United Kingdom","founded_year":null,"website":"https://r1therapeutics.com","x_handle":null,"followers":null,"logo":"https://recentfunding.com/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkL2ViNzc1NTU5MjgxYzQ3NTU5MTY1ZGVkMzhlYzZlZjMw","amount_usd":"80500000.00","announced_at":"2026-09-30T00:00:00.000Z","raise_source_url":"https://www.clinicaltrialsarena.com/news/r1-therapeutics-80m-fund-ap306-study/","raise_publisher":"clinicaltrialsarena.com","raise_provider":"crunchbase","sources":[],"investors":["Abingworth","Curie.Bio","DaVita Venture Group","F-Prime Capital","Samsara Biocapital","SymBiosis","U.S. Renal Care"],"flagged":false,"flagged_at":null,"source_links":{},"x_created_at":null,"domain_created_at":"2025-09-22","smart_follows":null,"days_early":null,"new_follows_7d":null,"trending_rank":null,"team_size":null,"team_source_url":null,"categories":["health-bio"]},"rounds":[{"stage":"series-a","amount_usd":"80500000.00","valuation_usd":null,"announced_at":"2026-09-30T00:00:00.000Z","source_url":"https://www.clinicaltrialsarena.com/news/r1-therapeutics-80m-fund-ap306-study/","source_publisher":"clinicaltrialsarena.com","source_provider":"crunchbase"}],"founders":[{"name":"Krishna Polu","x_handle":null,"linkedin_url":null,"avatar":"/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkLzM3ZDBhNzc4OTczNjRmYWFhOGUwYzUyYjEzY2YwYmQ2","role":"Founder","source_url":null,"other_companies":[]},{"name":"L. Mary Smith","x_handle":null,"linkedin_url":null,"avatar":"/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkLzYwNjJhZTZmNTBlYjQ3MjVhODExMGY1ZTliNzJhYTM3","role":"Founder","source_url":null,"other_companies":[]},{"name":"Barbara Gillespie","x_handle":null,"linkedin_url":null,"avatar":"/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkL2JhNWViOWM3N2I2NTQzYThiMGZjNTNjMzFkYjRkYzQ2","role":"Advisor","source_url":null,"other_companies":[]},{"name":"Ben Auspitz","x_handle":null,"linkedin_url":null,"avatar":"/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkLzk1MTYyNjg2NzBmNTQ1MzI4MTE4ZWYyOGQ1ZDQ0MmFk","role":"Board member","source_url":null,"other_companies":[]},{"name":"Chong Xu","x_handle":null,"linkedin_url":null,"avatar":"/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkL3YxNTA0NTk4MzUzL2d2eHl6YzdyY3hwazdiZ2h1cnV3LnBuZw","role":"Board member","source_url":null,"other_companies":[]},{"name":"Glenn Chertow","x_handle":null,"linkedin_url":null,"avatar":"/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkL2JiY2VmMWE0MGU5ODQ5OWRiMmQwMmE2ZDQ5NGZkZjE3","role":"Advisor","source_url":null,"other_companies":[]},{"name":"Sharon Moe","x_handle":null,"linkedin_url":null,"avatar":"/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkLzhmOTE2NGEwMWVlNDQ5ZmY4YTlkOWFlYjQ1MTQyM2I3","role":"Advisor","source_url":null,"other_companies":[]},{"name":"Tom Musgrave","x_handle":null,"linkedin_url":null,"avatar":"/logo/u/aHR0cHM6Ly9pbWFnZXMuY3J1bmNoYmFzZS5jb20vaW1hZ2UvdXBsb2FkLzVjMmY5NGRkNDYwZDQ3MjA4MWU3NGFiYTNhZmI3ODhh","role":"Board member","source_url":null,"other_companies":[]}]}